News from k-v pharmaceutical company A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Oct 20, 2014, 08:00 ET

Takeda and Orexigen Announce Availability of CONTRAVE® (naltrexone HCI and bupropion HCI) Extended-Release Tablets for Chronic Weight Management in Obese Adults

 Takeda Pharmaceutical Company Limited ("Takeda"), its wholly-owned subsidiary Takeda Pharmaceuticals U.S.A., Inc. and Orexigen®...

Sep 30, 2014, 07:30 ET

Par Pharmaceutical Begins Shipment of Generic Exforge®

 Par Pharmaceutical Companies, Inc. today announced that it has begun shipping all four strengths of amlodipine and valsartan tablets, the...

Sep 08, 2014, 12:24 ET

Par Pharmaceutical Resumes Shipment of Generic Precedex® Injection

Par Pharmaceutical Companies, Inc. today announced that it has resumed shipping dexmedetomidine hydrochloride (HCl) injection, EQ 100 mcg base/mL,...

Aug 28, 2014, 12:09 ET

Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS

Takeda Pharmaceutical Company Limited ("Takeda") today announced the completion of the post-marketing commitment and submissions of data from...

Aug 26, 2014, 09:00 ET
Boehringer Ingelheim logo.  (PRNewsFoto/Eli Lilly and Company)

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies

 Jardiance® (empagliflozin) tablets are now available by prescription in pharmacies across the United States, including Walgreens, Rite...

Aug 25, 2014, 08:25 ET

Janssen Affiliate Cilag GmbH International Acquires Covagen AG

Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired...

Aug 06, 2014, 10:54 ET

Par Pharmaceutical Announces Quarterly Conference Call

Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Wednesday, August 13, 2014 at 10:00 a.m. EDT to review...

Aug 04, 2014, 09:14 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Type 2 diabetes: Jentadueto® (linagliptin and metformin hydrochloride) tablets label updated to include new data on blood glucose reductions in treatment-naive adults with high baseline A1C

  The U.S. Prescribing Information for Jentadueto® (linagliptin and metformin hydrochloride) tablets now includes clinical trial data...

Aug 01, 2014, 23:26 ET
Jardiance (R)  (empagliflozin) 10 mg tablets* *The above image does not reflect the actual size of the tablet (PRNewsFoto/Eli Lilly and Company)

FDA approves Jardiance® (empagliflozin) tablets for adults with type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA)...

Jul 10, 2014, 09:00 ET

Takeda and Zinfandel Pharmaceuticals to Present Data at Upcoming Alzheimer's Association International Conference® Highlighting Innovative Approaches to Alzheimer's Disease Research and Development

 Takeda Pharmaceutical Company Limited ("Takeda") and its partner, Zinfandel Pharmaceuticals, Inc. ("Zinfandel"), will present data during...

Jul 09, 2014, 08:00 ET

Par Pharmaceutical Begins Shipment of Fluphenazine Decanoate Injection, USP

Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its...

Jun 17, 2014, 15:53 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Type 2 diabetes: Boehringer Ingelheim and Eli Lilly and Company announce resubmission of New Drug Application for empagliflozin to FDA

 Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced the resubmission of a New Drug...

Jun 17, 2014, 09:00 ET

Results of a New Study of Brintellix® (vortioxetine) vs. Escitalopram on Sexual Functioning in Well Treated MDD Patients Experiencing Treatment-Emergent Sexual Dysfunction

Takeda Pharmaceuticals Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced that the companies will present results about sexual...

Jun 16, 2014, 10:00 ET

ENTYVIO™ (vedolizumab) Now Available in the United States for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis and Crohn's Disease

 Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced the...

Jun 16, 2014, 06:30 ET

New CONNECT Study Presents data on Measures of Cognitive Performance in Adult Patients Treated with Brintellix® (vortioxetine) for Major Depressive Disorder

 Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced results from CONNECT, a new study that evaluated...

Jun 10, 2014, 14:34 ET

Strativa Pharmaceuticals Announces FDA Approval of Nascobal® (Cyanocobalamin, USP) Nasal Spray Single-Use Device

 Strativa Pharmaceuticals, the branded division of Par Pharmaceutical Companies, Inc., today announced that the U.S. Food and Drug...

May 20, 2014, 18:14 ET

FDA Approves Takeda's Entyvio™ (vedolizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the...

May 15, 2014, 12:45 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Type 2 diabetes: findings presented from retrospective analysis of pooled data examining linagliptin in African-American adults

Data from a retrospective pooled analysis of eight phase III trials (two 18-week and six 24-week) of linagliptin 5 mg once-daily, showed...

May 09, 2014, 09:00 ET

Pharmaceutical Executive Paul Williams Joins K-V Pharmaceutical Company as Head of Women's Healthcare Division

 Today, K-V Pharmaceutical Company ("KV") announced that Paul Williams – a seasoned executive with extensive experience in both neonatal...

May 07, 2014, 11:34 ET

Par Pharmaceutical Announces Quarterly Conference Call

Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Friday, May 16, 2014 at 9:30 a.m. EDT to review its...